| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 78 | 2019 | 1661 | 6.750 |
Why?
|
| Neoplasms | 72 | 2021 | 2757 | 4.810 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 37 | 2020 | 1227 | 4.080 |
Why?
|
| Neoplasm Recurrence, Local | 28 | 2021 | 1117 | 2.680 |
Why?
|
| Salvage Therapy | 12 | 2019 | 193 | 2.630 |
Why?
|
| Maximum Tolerated Dose | 49 | 2020 | 157 | 2.570 |
Why?
|
| Camptothecin | 18 | 2010 | 76 | 2.500 |
Why?
|
| Glioma | 24 | 2024 | 496 | 2.450 |
Why?
|
| Brain Stem Neoplasms | 10 | 2022 | 39 | 2.400 |
Why?
|
| Brain Neoplasms | 30 | 2020 | 1235 | 2.390 |
Why?
|
| Central Nervous System Neoplasms | 18 | 2024 | 194 | 2.340 |
Why?
|
| Drug Resistance, Neoplasm | 23 | 2020 | 714 | 2.190 |
Why?
|
| Indoles | 8 | 2016 | 180 | 2.160 |
Why?
|
| Antimetabolites, Antineoplastic | 13 | 2013 | 178 | 2.160 |
Why?
|
| Child, Preschool | 135 | 2024 | 13886 | 2.150 |
Why?
|
| Cyclophosphamide | 15 | 2020 | 419 | 2.020 |
Why?
|
| Meningeal Neoplasms | 15 | 2011 | 183 | 1.910 |
Why?
|
| Adolescent | 139 | 2024 | 19102 | 1.820 |
Why?
|
| Sarcoma, Ewing | 6 | 2019 | 113 | 1.800 |
Why?
|
| Child | 152 | 2024 | 24234 | 1.770 |
Why?
|
| Topotecan | 15 | 2020 | 49 | 1.700 |
Why?
|
| Bone Neoplasms | 11 | 2019 | 427 | 1.670 |
Why?
|
| Protein Kinase Inhibitors | 13 | 2021 | 522 | 1.660 |
Why?
|
| Dose-Response Relationship, Drug | 48 | 2020 | 1683 | 1.630 |
Why?
|
| Chemoradiotherapy | 3 | 2020 | 100 | 1.620 |
Why?
|
| Leukemia | 16 | 2019 | 375 | 1.580 |
Why?
|
| Macaca mulatta | 27 | 2010 | 494 | 1.580 |
Why?
|
| Pyrimidines | 11 | 2019 | 373 | 1.420 |
Why?
|
| Antineoplastic Agents, Alkylating | 12 | 2015 | 99 | 1.410 |
Why?
|
| Young Adult | 48 | 2024 | 8862 | 1.360 |
Why?
|
| Niacinamide | 3 | 2015 | 24 | 1.350 |
Why?
|
| Sirolimus | 3 | 2017 | 220 | 1.340 |
Why?
|
| Antibodies, Monoclonal | 8 | 2014 | 1007 | 1.300 |
Why?
|
| Medical Oncology | 6 | 2019 | 214 | 1.270 |
Why?
|
| Drug Administration Schedule | 36 | 2020 | 729 | 1.270 |
Why?
|
| Male | 155 | 2024 | 60082 | 1.250 |
Why?
|
| Antineoplastic Agents, Phytogenic | 7 | 2007 | 102 | 1.210 |
Why?
|
| Sarcoma | 5 | 2014 | 194 | 1.160 |
Why?
|
| Deoxycytidine | 6 | 2018 | 75 | 1.150 |
Why?
|
| Pyrroles | 5 | 2016 | 177 | 1.070 |
Why?
|
| Oncolytic Virotherapy | 4 | 2015 | 83 | 1.070 |
Why?
|
| Female | 133 | 2024 | 65489 | 1.020 |
Why?
|
| Area Under Curve | 28 | 2015 | 313 | 1.010 |
Why?
|
| Topoisomerase I Inhibitors | 4 | 2011 | 16 | 0.980 |
Why?
|
| Infusions, Intravenous | 33 | 2012 | 536 | 0.960 |
Why?
|
| Humans | 187 | 2024 | 123163 | 0.940 |
Why?
|
| Medulloblastoma | 15 | 2013 | 338 | 0.910 |
Why?
|
| Valproic Acid | 5 | 2020 | 165 | 0.890 |
Why?
|
| Enzyme Inhibitors | 11 | 2015 | 572 | 0.890 |
Why?
|
| Phenylurea Compounds | 2 | 2015 | 48 | 0.880 |
Why?
|
| Guanine | 5 | 2012 | 60 | 0.870 |
Why?
|
| Infant | 67 | 2024 | 12347 | 0.860 |
Why?
|
| Injections, Spinal | 16 | 2012 | 117 | 0.830 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2016 | 207 | 0.810 |
Why?
|
| Adult | 76 | 2020 | 29057 | 0.800 |
Why?
|
| Pyrazoles | 6 | 2017 | 303 | 0.800 |
Why?
|
| Rhabdomyosarcoma | 6 | 2015 | 200 | 0.790 |
Why?
|
| Pediatrics | 7 | 2019 | 1138 | 0.780 |
Why?
|
| Neuroblastoma | 11 | 2021 | 509 | 0.770 |
Why?
|
| Dacarbazine | 7 | 2014 | 86 | 0.770 |
Why?
|
| Glutamates | 3 | 2012 | 69 | 0.740 |
Why?
|
| Pyrazines | 5 | 2012 | 73 | 0.710 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 78 | 0.700 |
Why?
|
| Capecitabine | 2 | 2017 | 16 | 0.700 |
Why?
|
| Boronic Acids | 4 | 2012 | 48 | 0.680 |
Why?
|
| Administration, Oral | 17 | 2020 | 670 | 0.660 |
Why?
|
| Treatment Outcome | 46 | 2019 | 12129 | 0.640 |
Why?
|
| Benzimidazoles | 4 | 2020 | 129 | 0.630 |
Why?
|
| Recurrence | 15 | 2019 | 1422 | 0.610 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 5046 | 0.610 |
Why?
|
| Furans | 1 | 2018 | 27 | 0.610 |
Why?
|
| Ketones | 1 | 2018 | 24 | 0.600 |
Why?
|
| Quinazolines | 8 | 2013 | 175 | 0.600 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2017 | 804 | 0.590 |
Why?
|
| Arabinonucleosides | 3 | 2006 | 32 | 0.590 |
Why?
|
| Picornaviridae | 2 | 2014 | 20 | 0.590 |
Why?
|
| Pyridines | 6 | 2018 | 224 | 0.580 |
Why?
|
| Tablets | 2 | 2017 | 28 | 0.580 |
Why?
|
| Emaciation | 1 | 2017 | 2 | 0.570 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2014 | 28 | 0.560 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 42 | 0.550 |
Why?
|
| Survival Rate | 14 | 2020 | 1996 | 0.550 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 766 | 0.550 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 99 | 0.530 |
Why?
|
| Piperazines | 6 | 2010 | 230 | 0.520 |
Why?
|
| Cytarabine | 5 | 2006 | 98 | 0.520 |
Why?
|
| Hematologic Neoplasms | 3 | 2015 | 286 | 0.510 |
Why?
|
| Depsipeptides | 2 | 2006 | 10 | 0.500 |
Why?
|
| Neoplasm Staging | 13 | 2017 | 1213 | 0.490 |
Why?
|
| Reoviridae | 1 | 2015 | 38 | 0.490 |
Why?
|
| Prognosis | 14 | 2020 | 4507 | 0.490 |
Why?
|
| Organoplatinum Compounds | 3 | 2010 | 29 | 0.490 |
Why?
|
| Protein Kinase C beta | 1 | 2014 | 21 | 0.480 |
Why?
|
| Combined Modality Therapy | 17 | 2019 | 1239 | 0.480 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2010 | 57 | 0.470 |
Why?
|
| Thalidomide | 3 | 2010 | 36 | 0.460 |
Why?
|
| Phenylacetates | 3 | 2004 | 23 | 0.460 |
Why?
|
| Meninges | 2 | 2006 | 16 | 0.460 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 4 | 2020 | 45 | 0.460 |
Why?
|
| Wilms Tumor | 2 | 2015 | 111 | 0.450 |
Why?
|
| Half-Life | 12 | 2010 | 156 | 0.450 |
Why?
|
| Dioxoles | 2 | 2011 | 10 | 0.450 |
Why?
|
| Sulfonamides | 2 | 2013 | 259 | 0.440 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 91 | 0.420 |
Why?
|
| Fluorouracil | 1 | 2013 | 128 | 0.420 |
Why?
|
| Histones | 5 | 2013 | 526 | 0.420 |
Why?
|
| Meningitis, Aseptic | 1 | 2012 | 14 | 0.410 |
Why?
|
| Chromatography, High Pressure Liquid | 11 | 2006 | 338 | 0.410 |
Why?
|
| Tetrahydroisoquinolines | 2 | 2011 | 11 | 0.410 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2013 | 71 | 0.400 |
Why?
|
| Ependymoma | 5 | 2021 | 133 | 0.400 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2014 | 326 | 0.400 |
Why?
|
| Kidney Neoplasms | 3 | 2015 | 432 | 0.390 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2011 | 130 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2014 | 490 | 0.360 |
Why?
|
| Animals | 43 | 2021 | 33752 | 0.360 |
Why?
|
| Hydroxamic Acids | 4 | 2022 | 56 | 0.350 |
Why?
|
| Folic Acid Antagonists | 2 | 2007 | 17 | 0.340 |
Why?
|
| Supratentorial Neoplasms | 3 | 2021 | 37 | 0.330 |
Why?
|
| Biomarkers, Tumor | 4 | 2019 | 1430 | 0.330 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2010 | 137 | 0.330 |
Why?
|
| Central Nervous System Diseases | 3 | 2015 | 105 | 0.330 |
Why?
|
| Leukemic Infiltration | 2 | 2006 | 8 | 0.320 |
Why?
|
| Tissue Distribution | 4 | 2019 | 382 | 0.320 |
Why?
|
| Neutropenia | 11 | 2013 | 202 | 0.320 |
Why?
|
| Acyclovir | 1 | 2008 | 45 | 0.310 |
Why?
|
| Patient Participation | 2 | 2010 | 220 | 0.310 |
Why?
|
| Astrocytoma | 3 | 2022 | 103 | 0.310 |
Why?
|
| Valine | 1 | 2008 | 106 | 0.300 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2008 | 88 | 0.300 |
Why?
|
| Cytidine | 3 | 1993 | 9 | 0.300 |
Why?
|
| Paclitaxel | 4 | 2009 | 121 | 0.300 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2008 | 126 | 0.300 |
Why?
|
| Meningitis | 3 | 2006 | 99 | 0.290 |
Why?
|
| Metabolic Clearance Rate | 14 | 2009 | 142 | 0.290 |
Why?
|
| Catheters, Indwelling | 3 | 2004 | 155 | 0.270 |
Why?
|
| Sesquiterpenes | 1 | 2006 | 22 | 0.270 |
Why?
|
| Rhabdoid Tumor | 4 | 2011 | 49 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2015 | 413 | 0.260 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 300 | 0.260 |
Why?
|
| Carbazoles | 3 | 2008 | 32 | 0.260 |
Why?
|
| Osteosarcoma | 6 | 2016 | 257 | 0.260 |
Why?
|
| Phototherapy | 3 | 2012 | 35 | 0.260 |
Why?
|
| Prodrugs | 2 | 2006 | 59 | 0.260 |
Why?
|
| Cerebellar Neoplasms | 3 | 2007 | 282 | 0.260 |
Why?
|
| Azepines | 2 | 2019 | 61 | 0.260 |
Why?
|
| Teratoma | 4 | 2011 | 123 | 0.250 |
Why?
|
| Bortezomib | 4 | 2012 | 73 | 0.240 |
Why?
|
| Methotrexate | 5 | 2006 | 341 | 0.240 |
Why?
|
| Proteasome Inhibitors | 1 | 2004 | 60 | 0.240 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 861 | 0.240 |
Why?
|
| Models, Theoretical | 2 | 2004 | 356 | 0.240 |
Why?
|
| Neoplasm Proteins | 6 | 2015 | 667 | 0.240 |
Why?
|
| Injections, Intravenous | 7 | 2013 | 252 | 0.240 |
Why?
|
| Phenylbutyrates | 2 | 2004 | 54 | 0.230 |
Why?
|
| ErbB Receptors | 6 | 2013 | 284 | 0.230 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 183 | 0.230 |
Why?
|
| Farnesyltranstransferase | 3 | 2010 | 9 | 0.230 |
Why?
|
| Quinolones | 3 | 2010 | 54 | 0.230 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 52 | 0.220 |
Why?
|
| Gangliosides | 1 | 2024 | 63 | 0.220 |
Why?
|
| Benzamides | 7 | 2010 | 106 | 0.220 |
Why?
|
| Retreatment | 3 | 2019 | 88 | 0.220 |
Why?
|
| Doxorubicin | 5 | 2020 | 299 | 0.210 |
Why?
|
| Antiviral Agents | 3 | 1999 | 747 | 0.210 |
Why?
|
| Animal Husbandry | 1 | 2002 | 10 | 0.210 |
Why?
|
| Neoplasm Grading | 4 | 2024 | 267 | 0.210 |
Why?
|
| Immobilization | 1 | 2002 | 23 | 0.210 |
Why?
|
| Cerebrospinal Fluid | 4 | 2004 | 93 | 0.200 |
Why?
|
| Restraint, Physical | 1 | 2002 | 28 | 0.200 |
Why?
|
| Glutamine | 1 | 2003 | 195 | 0.200 |
Why?
|
| Polyethylene Glycols | 3 | 2017 | 217 | 0.200 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2011 | 211 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2016 | 71 | 0.200 |
Why?
|
| Mixed Function Oxygenases | 1 | 2002 | 32 | 0.200 |
Why?
|
| Social Environment | 1 | 2002 | 120 | 0.200 |
Why?
|
| Time Factors | 16 | 2018 | 6217 | 0.200 |
Why?
|
| Thienamycins | 1 | 2001 | 15 | 0.200 |
Why?
|
| Phenytoin | 1 | 2002 | 64 | 0.190 |
Why?
|
| Nanoshells | 2 | 2012 | 13 | 0.190 |
Why?
|
| Dexamethasone | 3 | 2012 | 272 | 0.190 |
Why?
|
| Pemetrexed | 3 | 2012 | 9 | 0.190 |
Why?
|
| Survival Analysis | 9 | 2013 | 1472 | 0.190 |
Why?
|
| Bevacizumab | 2 | 2020 | 63 | 0.190 |
Why?
|
| Age Factors | 6 | 2018 | 2802 | 0.190 |
Why?
|
| Oncolytic Viruses | 2 | 2013 | 71 | 0.190 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 53 | 0.180 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 136 | 0.180 |
Why?
|
| Neurofibroma, Plexiform | 2 | 2014 | 7 | 0.180 |
Why?
|
| Mass Spectrometry | 4 | 2006 | 326 | 0.180 |
Why?
|
| Taxoids | 2 | 1999 | 65 | 0.180 |
Why?
|
| Jugular Veins | 1 | 2000 | 75 | 0.180 |
Why?
|
| Anticonvulsants | 2 | 2009 | 371 | 0.180 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2009 | 20 | 0.170 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2012 | 94 | 0.170 |
Why?
|
| Behavior, Animal | 1 | 2002 | 477 | 0.170 |
Why?
|
| Phthalazines | 1 | 2019 | 14 | 0.170 |
Why?
|
| Neurofibromatosis 1 | 2 | 2014 | 60 | 0.170 |
Why?
|
| Models, Biological | 5 | 2010 | 1441 | 0.170 |
Why?
|
| Glucuronosyltransferase | 3 | 2009 | 69 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2017 | 133 | 0.160 |
Why?
|
| Health Planning Councils | 1 | 2019 | 2 | 0.160 |
Why?
|
| Prosthesis Implantation | 1 | 2000 | 143 | 0.160 |
Why?
|
| Blood-Brain Barrier | 3 | 2010 | 141 | 0.160 |
Why?
|
| Carboplatin | 3 | 2011 | 75 | 0.160 |
Why?
|
| Ganciclovir | 1 | 1999 | 102 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2019 | 877 | 0.160 |
Why?
|
| Immunoconjugates | 1 | 2018 | 35 | 0.150 |
Why?
|
| Anilides | 1 | 2018 | 48 | 0.150 |
Why?
|
| Neuroectodermal Tumors, Primitive | 3 | 2006 | 52 | 0.150 |
Why?
|
| Erwinia | 1 | 2017 | 3 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 2 | 2010 | 294 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2015 | 66 | 0.150 |
Why?
|
| Feasibility Studies | 3 | 2012 | 751 | 0.150 |
Why?
|
| Asparaginase | 1 | 2017 | 41 | 0.150 |
Why?
|
| Cisplatin | 3 | 2004 | 242 | 0.150 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2017 | 10 | 0.140 |
Why?
|
| Thrombocytopenia | 5 | 2013 | 228 | 0.140 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 17 | 0.140 |
Why?
|
| Ifosfamide | 3 | 2009 | 36 | 0.140 |
Why?
|
| Diencephalon | 1 | 2017 | 10 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 28 | 0.140 |
Why?
|
| Microtubules | 1 | 2018 | 197 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2017 | 26 | 0.140 |
Why?
|
| Radiotherapy Dosage | 3 | 2013 | 185 | 0.140 |
Why?
|
| Foot | 1 | 2017 | 63 | 0.140 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2014 | 56 | 0.130 |
Why?
|
| Drug Hypersensitivity | 1 | 2017 | 96 | 0.130 |
Why?
|
| Quinolines | 1 | 2017 | 96 | 0.130 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2022 | 74 | 0.130 |
Why?
|
| Benzoquinones | 3 | 2007 | 19 | 0.130 |
Why?
|
| Hand | 1 | 2017 | 102 | 0.130 |
Why?
|
| Busulfan | 2 | 2006 | 44 | 0.130 |
Why?
|
| Zalcitabine | 1 | 1995 | 4 | 0.130 |
Why?
|
| Nitriles | 2 | 2015 | 146 | 0.130 |
Why?
|
| Etoposide | 3 | 2006 | 117 | 0.130 |
Why?
|
| Aminoglycosides | 2 | 2008 | 45 | 0.130 |
Why?
|
| Treatment Failure | 2 | 2015 | 338 | 0.130 |
Why?
|
| Imatinib Mesylate | 5 | 2008 | 44 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 293 | 0.130 |
Why?
|
| Immunohistochemistry | 7 | 2007 | 1687 | 0.130 |
Why?
|
| Propionates | 1 | 2015 | 30 | 0.120 |
Why?
|
| Benzene Derivatives | 1 | 2015 | 19 | 0.120 |
Why?
|
| DNA Repair Enzymes | 2 | 2013 | 40 | 0.120 |
Why?
|
| Mice, SCID | 7 | 2013 | 571 | 0.120 |
Why?
|
| DNA Modification Methylases | 2 | 2013 | 43 | 0.120 |
Why?
|
| Gene Expression Profiling | 3 | 2011 | 1682 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2017 | 383 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 2 | 2014 | 240 | 0.120 |
Why?
|
| Sulfones | 1 | 2015 | 66 | 0.120 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 2047 | 0.120 |
Why?
|
| Tretinoin | 2 | 2010 | 116 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2008 | 255 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2001 | 842 | 0.120 |
Why?
|
| Growth Plate | 1 | 2014 | 20 | 0.120 |
Why?
|
| Hyperthermia, Induced | 2 | 2012 | 44 | 0.120 |
Why?
|
| Transcription Factors | 4 | 2021 | 2585 | 0.120 |
Why?
|
| Cell Line, Tumor | 10 | 2012 | 3273 | 0.120 |
Why?
|
| Posture | 1 | 1995 | 152 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2017 | 1388 | 0.110 |
Why?
|
| Syndrome | 1 | 2017 | 1115 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 865 | 0.110 |
Why?
|
| Indazoles | 1 | 2013 | 23 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1101 | 0.110 |
Why?
|
| Oligonucleotides | 1 | 2013 | 88 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2014 | 1610 | 0.110 |
Why?
|
| Pyridones | 1 | 2014 | 112 | 0.110 |
Why?
|
| Urate Oxidase | 2 | 2005 | 16 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2019 | 518 | 0.110 |
Why?
|
| Lymphoma | 2 | 2007 | 321 | 0.110 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 12 | 0.100 |
Why?
|
| Cohort Studies | 6 | 2014 | 4705 | 0.100 |
Why?
|
| Biological Availability | 2 | 2020 | 128 | 0.100 |
Why?
|
| Telomerase | 1 | 2013 | 161 | 0.100 |
Why?
|
| Texas | 1 | 2021 | 3555 | 0.100 |
Why?
|
| Uracil | 1 | 1992 | 14 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 467 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 1 | 2012 | 55 | 0.100 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 879 | 0.100 |
Why?
|
| Powders | 1 | 2011 | 25 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 490 | 0.100 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 4275 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1262 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 1582 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2010 | 227 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2008 | 25 | 0.100 |
Why?
|
| Vinblastine | 1 | 2011 | 46 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 340 | 0.090 |
Why?
|
| Mice | 13 | 2021 | 17492 | 0.090 |
Why?
|
| Lymphocytes | 1 | 1993 | 401 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 667 | 0.090 |
Why?
|
| Protein Binding | 2 | 2006 | 1740 | 0.090 |
Why?
|
| Acylation | 1 | 2010 | 16 | 0.090 |
Why?
|
| Lipocalins | 1 | 2011 | 25 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 459 | 0.090 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2011 | 56 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2010 | 37 | 0.090 |
Why?
|
| Thiourea | 1 | 2010 | 9 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 5 | 2007 | 1061 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 97 | 0.090 |
Why?
|
| Altruism | 1 | 2010 | 25 | 0.090 |
Why?
|
| Epothilones | 1 | 2010 | 2 | 0.090 |
Why?
|
| Amifostine | 2 | 2003 | 14 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 203 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2011 | 408 | 0.080 |
Why?
|
| Acridines | 2 | 2000 | 8 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 191 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2007 | 653 | 0.080 |
Why?
|
| Imidazoles | 1 | 2010 | 199 | 0.080 |
Why?
|
| Bone Marrow | 2 | 2008 | 323 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 1339 | 0.080 |
Why?
|
| Melphalan | 2 | 2002 | 49 | 0.080 |
Why?
|
| Acetylation | 2 | 2006 | 166 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 813 | 0.080 |
Why?
|
| Drug Interactions | 3 | 2009 | 254 | 0.080 |
Why?
|
| Carboxylic Acids | 1 | 2008 | 24 | 0.080 |
Why?
|
| Metalloporphyrins | 1 | 2008 | 4 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3543 | 0.080 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2008 | 3 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2011 | 3316 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2006 | 459 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2005 | 54 | 0.080 |
Why?
|
| Vincristine | 3 | 2020 | 195 | 0.080 |
Why?
|
| Disease Progression | 4 | 2014 | 2026 | 0.080 |
Why?
|
| Analgesics, Opioid | 2 | 2005 | 402 | 0.080 |
Why?
|
| Pons | 1 | 2008 | 32 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2008 | 118 | 0.080 |
Why?
|
| Glucuronates | 1 | 2008 | 6 | 0.080 |
Why?
|
| Carmustine | 1 | 2008 | 26 | 0.080 |
Why?
|
| Hydrazines | 1 | 2008 | 28 | 0.070 |
Why?
|
| Headache | 2 | 2007 | 108 | 0.070 |
Why?
|
| Arsenicals | 1 | 2007 | 15 | 0.070 |
Why?
|
| Oxides | 1 | 2007 | 15 | 0.070 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2007 | 24 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2011 | 678 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2017 | 6032 | 0.070 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 1088 | 0.070 |
Why?
|
| Thionucleotides | 1 | 2007 | 19 | 0.070 |
Why?
|
| Cell Survival | 4 | 2006 | 806 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 64 | 0.070 |
Why?
|
| Biomarkers | 3 | 2012 | 2946 | 0.070 |
Why?
|
| Drug Delivery Systems | 2 | 2007 | 182 | 0.070 |
Why?
|
| Lactams, Macrocyclic | 1 | 2007 | 18 | 0.070 |
Why?
|
| Cell Division | 2 | 2005 | 780 | 0.070 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 61 | 0.070 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2007 | 74 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2021 | 16021 | 0.070 |
Why?
|
| Liposomes | 2 | 2004 | 168 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2007 | 312 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2013 | 1100 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 62 | 0.070 |
Why?
|
| Heart | 1 | 2011 | 723 | 0.070 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2008 | 59 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2008 | 421 | 0.060 |
Why?
|
| Piperidines | 1 | 2007 | 198 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 82 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2008 | 369 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 262 | 0.060 |
Why?
|
| Adenine Nucleotides | 1 | 2005 | 41 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2006 | 229 | 0.060 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 12 | 0.060 |
Why?
|
| Aziridines | 2 | 1998 | 11 | 0.060 |
Why?
|
| Rituximab | 1 | 2006 | 155 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 603 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 245 | 0.060 |
Why?
|
| Apoptosis | 3 | 2010 | 1781 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 94 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 94 | 0.060 |
Why?
|
| Pulse Therapy, Drug | 1 | 2004 | 7 | 0.060 |
Why?
|
| Isoquinolines | 1 | 2005 | 40 | 0.060 |
Why?
|
| Hepatoblastoma | 1 | 2007 | 178 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2006 | 179 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 1414 | 0.060 |
Why?
|
| Pancreatitis | 3 | 2008 | 129 | 0.060 |
Why?
|
| DNA, Neoplasm | 3 | 2008 | 300 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2007 | 231 | 0.060 |
Why?
|
| Thiophenes | 1 | 2005 | 60 | 0.060 |
Why?
|
| Algorithms | 1 | 2011 | 1592 | 0.060 |
Why?
|
| Morphine | 1 | 2005 | 87 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2007 | 455 | 0.060 |
Why?
|
| Peptides | 1 | 2008 | 794 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 186 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.060 |
Why?
|
| Spinal Puncture | 1 | 2004 | 53 | 0.060 |
Why?
|
| Hyperuricemia | 1 | 2005 | 36 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2004 | 111 | 0.060 |
Why?
|
| Philadelphia Chromosome | 1 | 2004 | 40 | 0.060 |
Why?
|
| Cellular Senescence | 1 | 2005 | 161 | 0.060 |
Why?
|
| Cyclins | 1 | 2004 | 101 | 0.060 |
Why?
|
| Triazines | 1 | 2004 | 29 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 321 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2004 | 31 | 0.060 |
Why?
|
| Affect | 1 | 2005 | 154 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2006 | 510 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 1292 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2000 | 678 | 0.060 |
Why?
|
| Patient Selection | 5 | 2011 | 685 | 0.050 |
Why?
|
| Biotransformation | 1 | 2003 | 49 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2003 | 44 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2008 | 635 | 0.050 |
Why?
|
| Nausea | 2 | 2007 | 97 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 204 | 0.050 |
Why?
|
| Genotype | 1 | 2009 | 2541 | 0.050 |
Why?
|
| Veterinary Medicine | 1 | 2002 | 8 | 0.050 |
Why?
|
| Neoplasm Transplantation | 3 | 2010 | 369 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 353 | 0.050 |
Why?
|
| Vomiting | 2 | 2007 | 115 | 0.050 |
Why?
|
| Drug Resistance | 2 | 1993 | 256 | 0.050 |
Why?
|
| Ondansetron | 1 | 2002 | 10 | 0.050 |
Why?
|
| Pineal Gland | 1 | 2002 | 17 | 0.050 |
Why?
|
| Pinealoma | 1 | 2002 | 19 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 378 | 0.050 |
Why?
|
| Phenobarbital | 1 | 2002 | 36 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 103 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1999 | 96 | 0.050 |
Why?
|
| Radiotherapy | 3 | 2008 | 135 | 0.050 |
Why?
|
| Pain | 1 | 2005 | 470 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2002 | 69 | 0.050 |
Why?
|
| Infant, Newborn | 6 | 2008 | 8106 | 0.050 |
Why?
|
| Middle Aged | 5 | 2007 | 25992 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 1305 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 1174 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2001 | 34 | 0.050 |
Why?
|
| Pharmaceutic Aids | 1 | 2000 | 3 | 0.050 |
Why?
|
| Toxicity Tests | 1 | 2001 | 35 | 0.050 |
Why?
|
| Povidone | 1 | 2000 | 5 | 0.050 |
Why?
|
| Cefazolin | 1 | 2000 | 20 | 0.050 |
Why?
|
| Drug Eruptions | 3 | 2008 | 33 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2002 | 260 | 0.040 |
Why?
|
| Isoflurane | 1 | 2000 | 45 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2000 | 110 | 0.040 |
Why?
|
| Anesthetics, Inhalation | 1 | 2000 | 46 | 0.040 |
Why?
|
| Uric Acid | 1 | 2001 | 94 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 3666 | 0.040 |
Why?
|
| Phenylenediamines | 1 | 2000 | 25 | 0.040 |
Why?
|
| Subarachnoid Space | 1 | 2000 | 24 | 0.040 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1999 | 19 | 0.040 |
Why?
|
| Thioguanine | 1 | 1999 | 21 | 0.040 |
Why?
|
| Penicillins | 1 | 2000 | 154 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2000 | 137 | 0.040 |
Why?
|
| Buprenorphine | 1 | 2000 | 92 | 0.040 |
Why?
|
| Carbamates | 1 | 1999 | 57 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2001 | 136 | 0.040 |
Why?
|
| Burkitt Lymphoma | 1 | 2001 | 145 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2001 | 162 | 0.040 |
Why?
|
| Hospitals, Pediatric | 3 | 2011 | 779 | 0.040 |
Why?
|
| Molecular Structure | 2 | 2009 | 285 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2011 | 98 | 0.040 |
Why?
|
| Research Design | 1 | 2002 | 685 | 0.040 |
Why?
|
| Cytotoxins | 1 | 1998 | 20 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2009 | 239 | 0.040 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1998 | 18 | 0.040 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2008 | 19 | 0.040 |
Why?
|
| Sarcoma, Clear Cell | 1 | 1998 | 20 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 801 | 0.040 |
Why?
|
| Cell Cycle | 3 | 2005 | 614 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 111 | 0.040 |
Why?
|
| Bone Marrow Diseases | 2 | 2008 | 40 | 0.040 |
Why?
|
| SMARCB1 Protein | 2 | 2011 | 35 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 296 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 217 | 0.040 |
Why?
|
| Diarrhea | 2 | 2010 | 316 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 1386 | 0.040 |
Why?
|
| Fatigue | 2 | 2010 | 216 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2008 | 253 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2010 | 2814 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 1005 | 0.030 |
Why?
|
| Seizures | 1 | 2002 | 874 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 53 | 0.030 |
Why?
|
| Lamivudine | 1 | 1995 | 25 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1997 | 221 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2011 | 214 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1995 | 103 | 0.030 |
Why?
|
| Brain Stem | 1 | 1996 | 115 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 2 | 2010 | 494 | 0.030 |
Why?
|
| Glucosides | 2 | 2008 | 46 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2005 | 75 | 0.030 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2015 | 62 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 157 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2015 | 66 | 0.030 |
Why?
|
| Drug Evaluation | 2 | 1992 | 111 | 0.030 |
Why?
|
| Uridine Kinase | 1 | 1993 | 2 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 27 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 1993 | 31 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2002 | 1198 | 0.030 |
Why?
|
| Platelet Count | 2 | 2003 | 133 | 0.030 |
Why?
|
| Ribonucleotides | 1 | 1993 | 36 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1993 | 155 | 0.030 |
Why?
|
| DNA Repair | 2 | 2008 | 579 | 0.030 |
Why?
|
| Glioblastoma | 1 | 1996 | 334 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 382 | 0.030 |
Why?
|
| Didanosine | 1 | 1992 | 5 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 543 | 0.020 |
Why?
|
| Retroviridae Infections | 1 | 1991 | 10 | 0.020 |
Why?
|
| United States | 3 | 2018 | 10631 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 2394 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1993 | 354 | 0.020 |
Why?
|
| Thiotepa | 1 | 1991 | 15 | 0.020 |
Why?
|
| Injections, Intraventricular | 2 | 2002 | 65 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 1995 | 478 | 0.020 |
Why?
|
| Carbohydrate Sequence | 1 | 2011 | 17 | 0.020 |
Why?
|
| Asparagine | 1 | 2011 | 22 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 42 | 0.020 |
Why?
|
| Philadelphia | 1 | 2011 | 25 | 0.020 |
Why?
|
| Trypsin | 1 | 2011 | 95 | 0.020 |
Why?
|
| Mercaptopurine | 1 | 1991 | 71 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 59 | 0.020 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2010 | 8 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2010 | 57 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 41 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 2010 | 28 | 0.020 |
Why?
|
| Azacitidine | 1 | 2010 | 54 | 0.020 |
Why?
|
| Hyperbilirubinemia | 1 | 2010 | 41 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 262 | 0.020 |
Why?
|
| Hypokalemia | 1 | 2010 | 41 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2015 | 811 | 0.020 |
Why?
|
| Species Specificity | 1 | 1990 | 549 | 0.020 |
Why?
|
| Dogs | 1 | 1990 | 765 | 0.020 |
Why?
|
| DNA Damage | 1 | 1993 | 505 | 0.020 |
Why?
|
| Exanthema | 1 | 2010 | 68 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 48 | 0.020 |
Why?
|
| Incidence | 1 | 1997 | 3047 | 0.020 |
Why?
|
| Steroids | 1 | 2010 | 201 | 0.020 |
Why?
|
| Proteome | 1 | 2011 | 233 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 229 | 0.020 |
Why?
|
| Hallucinations | 1 | 2009 | 26 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 13 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 1997 | 2838 | 0.020 |
Why?
|
| Lomustine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Arthralgia | 1 | 2009 | 56 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 527 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2007 | 1870 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2008 | 35 | 0.020 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2008 | 13 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2002 | 151 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2010 | 388 | 0.020 |
Why?
|
| Sarcoma, Synovial | 1 | 2008 | 21 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 36 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 50 | 0.020 |
Why?
|
| Infrared Rays | 1 | 2007 | 20 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2008 | 82 | 0.020 |
Why?
|
| Dermatitis | 1 | 2007 | 25 | 0.020 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2007 | 20 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2006 | 1907 | 0.020 |
Why?
|
| Water-Electrolyte Balance | 1 | 2007 | 76 | 0.020 |
Why?
|
| Proteomics | 1 | 2011 | 479 | 0.020 |
Why?
|
| Bilirubin | 1 | 2008 | 120 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 23 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 94 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 31 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 263 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 45 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 68 | 0.020 |
Why?
|
| Lasers | 1 | 2007 | 115 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 105 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 137 | 0.020 |
Why?
|
| Carcinogenicity Tests | 1 | 2006 | 20 | 0.020 |
Why?
|
| Constipation | 1 | 2007 | 113 | 0.020 |
Why?
|
| Procarbazine | 1 | 2006 | 13 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 126 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2696 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 239 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2006 | 37 | 0.020 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2006 | 18 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2006 | 54 | 0.020 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2006 | 14 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 2527 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2007 | 222 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3868 | 0.020 |
Why?
|
| Brain | 2 | 2012 | 2961 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2006 | 121 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1151 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2007 | 306 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 567 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 171 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2005 | 146 | 0.020 |
Why?
|
| Cyclin D3 | 1 | 2004 | 10 | 0.020 |
Why?
|
| Cyclin D2 | 1 | 2004 | 14 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 194 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2004 | 16 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2004 | 38 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 77 | 0.010 |
Why?
|
| Quality of Life | 1 | 2014 | 1929 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 85 | 0.010 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2004 | 16 | 0.010 |
Why?
|
| Aniline Compounds | 1 | 2004 | 19 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 3654 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2010 | 987 | 0.010 |
Why?
|
| Pneumonia | 1 | 2007 | 325 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 123 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2006 | 208 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 3249 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 661 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 67 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 757 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 531 | 0.010 |
Why?
|
| DNA Adducts | 1 | 2003 | 78 | 0.010 |
Why?
|
| Monosomy | 1 | 2002 | 24 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 217 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2002 | 102 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 1584 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 301 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 1734 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 803 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 550 | 0.010 |
Why?
|
| Phosphorus | 1 | 2001 | 55 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2006 | 1019 | 0.010 |
Why?
|
| Probenecid | 1 | 2000 | 4 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 3091 | 0.010 |
Why?
|
| Uricosuric Agents | 1 | 2000 | 5 | 0.010 |
Why?
|
| General Surgery | 1 | 2002 | 203 | 0.010 |
Why?
|
| Aldehyde Oxidase | 1 | 1999 | 6 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2000 | 100 | 0.010 |
Why?
|
| HIV Infections | 1 | 1992 | 1869 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1266 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 2000 | 81 | 0.010 |
Why?
|
| Filgrastim | 1 | 1999 | 15 | 0.010 |
Why?
|
| Mutation | 1 | 2013 | 5773 | 0.010 |
Why?
|
| Anemia | 1 | 2003 | 340 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 2586 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 2306 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2002 | 638 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 1998 | 7 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1999 | 966 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1995 | 32 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 2056 | 0.010 |
Why?
|
| Haplorhini | 1 | 1994 | 123 | 0.010 |
Why?
|
| Tibia | 1 | 1994 | 70 | 0.010 |
Why?
|
| Anxiety | 1 | 2000 | 952 | 0.010 |
Why?
|
| Neurons | 1 | 2004 | 1933 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 6371 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 10008 | 0.010 |
Why?
|
| Absorption | 1 | 1992 | 52 | 0.010 |
Why?
|
| Drug Industry | 1 | 1991 | 46 | 0.010 |
Why?
|
| Acute Disease | 1 | 1994 | 1094 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1995 | 2106 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 232 | 0.010 |
Why?
|
| Aged | 1 | 2005 | 19080 | 0.000 |
Why?
|